Skip to main content
. 2018 Dec 3;11:8655–8672. doi: 10.2147/OTT.S186606

Figure 6.

Figure 6

Changes in motility of the TM4SF5-expressing pancreatic cancer cells after the humanized anti-hTM4SF5 monoclonal antibody treatment.

Notes: PANC02-mock and PANC02-hTM4SF5 cells were treated with normal IgG control or humanized anti-hTM4SF5 monoclonal antibody (anti-hTM4SF5 mAb), and motility was examined. (A) Wound healing activity was examined at the indicated time points. Scale bar, 200 µm. (B, C) The migratory and invasive properties. To measure the migration (B) and invasion (C) activity, the migrated and invaded cells on the lower sides of the transwell chambers were counted after incubation with the indicated materials. Scale bar, 100 µm. The percentage of cells migrated into wound, and the numbers of migrated or invaded cells were measured and compared (graphs). Values are the mean±SEM. *P<0.05, ***P<0.005 vs normal IgG control.

Abbreviation: SEM, standard error of the mean.